“We are at a pivotal moment in the journey of EmeritusDX. With the exceptional combined leadership of our newly onboarded team members, we feel confident that EmeritusDX is now set-up for even greater success,” said Chief Executive Officer Robert Embree.
IRVINE, Calif. (PRWEB) February 22, 2023
EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the expansion of their national sales team with the hiring of key personnel within strategic territories. These experienced sales leaders join a national, world-class team that is focused on accelerating the company's growth. As EmeritusDX scales its business and readies itself for numerous product launches, these hires will play an integral role in market expansion and adoption.
“We are at a pivotal moment in the journey of EmeritusDX. Nothing is more important than bringing in top sales talent to drive new customer-centric programs and build a robust sales pipeline. With the exceptional combined leadership of our newly onboarded team members, we feel confident that EmeritusDX is now set-up for even greater success,” said Chief Executive Officer Robert Embree.
With a presence in over 20 states, EmeritusDX has seen a meteoric rise over the past two years. The additional sales leaders will not only add to the number of states the company services, they will also help educate clients on new tests that will be launched in the upcoming months.
“We are excited about our product pipeline. Our R&D Team has been working diligently to develop tests that deliver actionable clinical information. We continue to innovate and our sales team plays a vital role in bringing these solutions to our clients,’ said Embree.
The recent additions cover the states of Arizona, California, Oregon and Washington. EmeritusDX has plans to continue to add sales in the Midwest later in the year.
EmeritusDX is a cancer diagnostic and information company. Our expertise is in delivering actionable clinical information. Within our world-class laboratory, we perform testing that guides the diagnosis and treatment of cancer patients. Our partners include hospital and private pathology laboratories, biotechnology companies, academic institutions, contract research and pharmaceutical development organizations, and more. We understand the dependency on our accurate and timely results and our commitment to excellence in this regard is unwavering.
If you would like more information about this topic, please call 800-959-2846 or email firstname.lastname@example.org